-
公开(公告)号：EP2291395B2
公开(公告)日：2018-11-14
申请号：EP09745570.3
申请日：2009-05-14
发明人： STEVANOVIC, Stefan , GOUTTEFANGES, Cécile , RAMMENSEE, Hans-Georg , WEINSCHENK, Toni , LEWANDROWSKI, Peter
CPC分类号： A61K38/10 , A61K39/0011 , C07H21/00 , C07K7/08 , C07K14/4747 , C07K14/4748 , C07K14/7056 , C07K16/18 , C12N15/10 , C12N15/86
摘要： The present invention relates to peptides, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：EP3111952B1
公开(公告)日：2018-10-31
申请号：EP16179241.1
申请日：2009-09-28
发明人： SCHOOR, Oliver , HILF, Norbert , WEINSCHENK, Toni , TRAUTWEIN, Claudia , WALTER, Steffen , SINGH, Harpreet
CPC分类号： C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 25 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
33.发明公开
公开(公告)号：EP3387008A1
公开(公告)日：2018-10-17
申请号：EP16805348.6
申请日：2016-11-24
发明人： MAHR, Andrea , WEINSCHENK, Toni , WIEBE, Anita , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet
IPC分类号： C07K14/47
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5158 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/7051 , C07K14/70539 , C07K16/2833 , C07K16/30 , C07K2317/34 , C12N5/0636 , C12N15/115 , C12N2310/16
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
34.发明公开NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS 审中-公开用于免疫治疗肾细胞癌（RCC）和其他癌症的肽和支架的新型肽和组合
公开(公告)号：EP3277310A1
公开(公告)日：2018-02-07
申请号：EP16715808.8
申请日：2016-03-24
发明人： MAHR, Andrea , WEINSCHENK, Toni , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet , SONG, Colette
CPC分类号： A61K39/0011 , A61K35/17 , A61K2035/124 , A61K2039/505 , A61K2039/5158 , A61K2039/572 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/18 , C07K16/2833 , C07K16/3038 , C07K2317/73 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N5/0636 , C12N15/115 , C12N2310/16 , G06F19/20
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
35.发明公开NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER CANCERS 审中-公开用于免疫胰腺癌和其他癌症的新型肽和肽的组合
公开(公告)号：EP3270952A1
公开(公告)日：2018-01-24
申请号：EP16710223.5
申请日：2016-03-17
发明人： WEINSCHENK, Toni , FRITSCHE, Jens , SINGH, Harpreet , MAHR, Andrea , OTT, Martina , WAGNER, Claudia , SCHOOR, Oliver
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5158 , C07K14/4748 , C07K14/70539 , C07K16/18 , C07K2319/00 , C12N15/115 , C12N2310/16
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
36.发明公开NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS 审中-公开新型免疫疗法针对不同肿瘤，包括神经和脑肿瘤
公开(公告)号：EP3124043A1
公开(公告)日：2017-02-01
申请号：EP16179214.8
申请日：2009-09-28
发明人： SCHOOR, Oliver , HILF, Norbert , WEINSCHENK, Toni , TRAUTWEIN, Claudia , WALTER, Steffen , SINGH, Harpreet
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/06 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
摘要翻译： 本发明涉及肽，核酸和细胞免疫治疗方法中使用。 特别地，本发明涉及癌症的免疫疗法。 本发明进一步更涉及肿瘤相关细胞毒性T细胞（CTL）肽表位，单独或与其它肿瘤相关肽组合并用作疫苗组合物的活性药物成分并刺激抗肿瘤免疫应答。 本发明涉及并能在疫苗组合物可用于引发抗肿瘤免疫应答从HLA I类和人肿瘤细胞的II分子衍生的30个肽序列及其变体。
-
37.发明公开
公开(公告)号：EP2291395A1
公开(公告)日：2011-03-09
申请号：EP09745570.3
申请日：2009-05-14
发明人： STEVANOVIC, Stefan , GOUTTEFANGES, Cécile , RAMMENSEE, Hans-Goerg , WEINSCHENK, Toni , LEWANDROWSKI, Peter
CPC分类号： A61K38/10 , A61K39/0011 , C07H21/00 , C07K7/08 , C07K14/4747 , C07K14/4748 , C07K14/7056 , C07K16/18 , C12N15/10 , C12N15/86
摘要： The present invention relates to peptides, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：EP2183361A1
公开(公告)日：2010-05-12
申请号：EP08785107.7
申请日：2008-07-25
发明人： SCHOOR, Oliver , HILF, Norbert , WEINSCHENK, Toni , TRAUTWEIN, Claudia , WALTER, Steffen , SINGH, Harpreet
CPC分类号： A61K35/17 , A61K38/00 , C07K7/06 , C07K7/08 , C07K14/4748 , C12N5/0638
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-rumor immune responses.
-
39.发明公开TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE 有权人性化LEUKOZYTENANTIGEN-（HLA）I类或II类分子结合肽与肿瘤相关的并且在连接立靠在癌症疫苗
公开(公告)号：EP1922334A1
公开(公告)日：2008-05-21
申请号：EP06777167.5
申请日：2006-09-05
CPC分类号： C07K14/4748
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
-
40.发明公开
公开(公告)号：EP4461371A2
公开(公告)日：2024-11-13
申请号：EP24199595.0
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
IPC分类号： A61P35/00
摘要： The current invention relates to a peptide comprising the sequence of SEQ ID NO: 5, a binding molecule specifically binding to the peptide, a nucleic acid encoding the peptide or the binding molecule, a host cell comprising the nucleic acid and the use of the peptide, the binding molecule, the nucleic acid or the host cell in medicine, in particular in the treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
125 条记录 (耗时 0.053 秒)
